Rapport Therapeutics, Inc. 8-K

What Happened
On May 7, 2026, Rapport Therapeutics, Inc. announced its financial results and business highlights for the quarter ended March 31, 2026 and furnished the related press release as Exhibit 99.1 to a Form 8‑K. The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) and the filing is signed by CFO Troy Ignelzi.

Key Details

• Announcement date: May 7, 2026; reporting period: quarter ended March 31, 2026.
• Item 2.02 invoked: Results of operations and financial condition were reported.
• Exhibit 99.1: Press release furnished with the detailed quarterly results and business highlights.
• Form signed by: Troy Ignelzi, Chief Financial Officer.

Why It Matters
This 8‑K provides the company’s latest quarterly results and operational update — key information for investors tracking earnings, revenue, cash position, R&D progress and near‑term outlook. Because the filing furnishes a press release (Exhibit 99.1), investors should review that exhibit for the specific numeric results and any business or pipeline developments disclosed.